Beefing Up Diversity Efforts, Wyeth Teams with Wesley Brown & Bartle
Wyeth Pharmaceuticals has selected Wesley Brown & Bartle (WB&B), the nationâ€™s leading diversity search firm, for its â€œProject Accessâ€? initiative, company executives report.
â€œThe goal of Project Access is to further enhance Wyethâ€™s workforce diversity through a strategic initiative focused on the recruitment of highly qualified women and people of color,â€? said Robert R. Ruffolo, Jr., who is President, Wyeth Research and also serves as Senior Vice President, Wyeth.
â€œThe WBB/Wyeth alliance will help Wyeth build ongoing pipelines of diverse bench strength at the Ph.D. and M.D. levels, in order to support the companyâ€™s long-term commitment to multi-cultural inclusion in its workforce,â€? Dr. Ruffolo, said.
Wyeth Pharmaceuticals and Wyeth Research employ more than 44,000 people Worldwideâ€”with the goal of improving the health of people around the world. Wyeth Research will further strengthen its workforce by hiring a group of talented MDs and Ph.D.s, with an emphasis on top performers representing the full range of diversity.
Wyeth picked WB&B as its strategic diversity sourcing partner in this project in part because WB&B has established the foremost record of diversity management staffing in corporate America, officials said. WB&B has been recognized by a variety of authorities such as FORTUNE, Crainâ€™s, The Wall Street Journal and the top management consulting and search firms in this arena for their significant track record of building balanced diverse workforces.
â€œIt is a privilege for our organization to work in partnership with a company like Wyeth, which has such a distinguished history of enhancing the health and welfare of people all over the globe,â€? said Kenneth Arroyo Roldan, CEO of Wesley Brown & Bartle. He is the first Hispanic head of a national search organization.
â€œWyeth has an impressive track record of hiring talented people, and our firm will do our very best to complement the companyâ€™s ongoing commitment to embracing the â€˜best and the brightestâ€™ reflective of a full array of ethnic and cultural backgrounds,â€? he added.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading products in the areas of womenâ€™s health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
The Companyâ€™s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.